Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma

Journal of Experimental Medicine

Volumn 198, Issue 10, 2003, Pages 1475-1485

  Sangaletti, Sabina ^a   Stoppacciaro, Antonella ^b   Guiducci, Cristiana ^a   Torrisi, Maria Rosaria ^b   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Extracellular matrix; Leukocyte infiltration; Osteonectin; Tumor host interactions

Indexed keywords

COLLAGEN TYPE 4; OSTEONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CARCINOMA CELL; CELL INFILTRATION; CHIMERA; COLLAGEN DEFECT; CONTROLLED STUDY; GENETIC LINKAGE; HOST CELL; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR CELL; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; WILD TYPE;

ANIMALS; CHIMERA; COLLAGEN TYPE IV; FEMALE; IMMUNOHISTOCHEMISTRY; LEUKOCYTES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; OSTEONECTIN; STROMAL CELLS;

EID: 0345016887     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030202     Document Type: Article

References (60)

1. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet. 17:539-544.
2. Coussens, L.M., and Z. Werb. 2001. Inflammatory cells and cancer: think different! J. Exp. Med. 19:23-26.
3. Moore, R., D. Owens, G. Stamp, C. Arnott, F. Burke, N. East, H. Holdsworth, L. Turner, B. Rollins, M. Pasparakis, et al. 1999. Tumour necrosis factor-α deficient mice are resistant to skin carcinogenesis. Nat. Med. 5:828-831.
4. Vidal-Vanaclocha, F., G. Fantuzzi, and L. Mendoza. 2000. IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. USA. 97:734-739.
5. Wiktor-Jedrzejczak, W., A. Bartocci, A.W. Ferrante, A. Ahmed-Ansari, K.W. Sell, J.W. Pollard, and E.R. Stanley. 1990. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. USA. 87:4828-4832.
6. Yoshida, H., S. Hayashi, T. Kunisada, M. Ogawa, S. Nishikawa, H. Okamura, T. Sudo, L.D. Shultz, and S. Nishikawa. 1990. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 31:442-444.
7. Nowicki, A., J. Szenajch, G. Ostrowska, A. Wojtowicz, K. Wojtowicz, A.A. Kruszewski, M. Maruszynski, S.L. Aukerman, and W. Wiktor-Jedrzejczak. 1996. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer. 65:112-119.
8. Lin, E.Y., A.V. Nguyen, R.G. Russel, and J.W. Pollard. 2001. Colony-stimulating factor I promotes progression of mammary tumor to malignancy. J. Exp. Med. 193:727-740.
9. Coussens, L.M., C.L. Tinkle, D. Hanahan, and Z. Werb. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 103:481-490.
10. Huang, S., M. Van Arsdall, S. Tedjarati, M. McCarty, W. Wu, R. Langley, and I.J. Fidler. 2002. Contributions of stromal metaUoproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94:1134-1142.
11. Clezardin, P., L. Malaval, A.S. Ehrensperger, P.D. Delmas, M. Dechavanne, and J.L. McGregor. 1988. Complex formation of human thrombospondin with osteonectin. Eur. J. Biochem. 175:275-284.
12. Rosenblatt, S., J.A. Bassuk, C.E. Alpers, E.H. Sage, R. Timpl, and K.T. Preissner. 1997. Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem. J. 324:311-319.
13. Mayer, U., M. Aumailley, K. Mann, R. Timpl, and J. Engel. 1991. Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV. Eur. J. Biochem. 198:141-150.
14. Bradshaw, A.D., and E.H. Sage. 2001. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107:1049-1054.
15. Martinek, N., R. Zou, M. Berg, J. Sodek, and M. Ringuette. 2002. Evolutionary conservation and association of SPARC with the basal lamina in Drosophila. Dev. Genes Evol. 212:124-133.
16. Swaroop, A., B.L. Hogan, and U. Francke. 1988. Molecular analysis of the cDNA of human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics. 2:37-47.
17. Hasselaar, P., and E.H. Sage. 1992. SPARC antagonizes the effect of bFGF on the migration of bovine aortic endothelial cells. J. Cell. Biochem. 49:272-283.
18. Raines, E.W., T.F. Lane, M.L. Iruela-Arispe, R. Ross, and E.H. Sage. 1992. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. USA. 89:1281-1285.
19. Kupprion, C., K. Motamed, and E.H. Sage. 1999. SPARC inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273:29635-29640.
20. Delany, A.M., I. Kalajzic, A.D. Bradshaw, E.H. Sage, and E. Canalis. 2003. Osteonectin null mutation compromises osteoblast formation, maturation, and survival. Endocrinology. 144:2588-2596.
21. Yan, Q., and E.H. Sage. 1999. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47:1495-1506.
22. Colombo, M.P., G. Ferrari, G. Biondi, D. Galasso, C.C. Howe, and G. Parmiani. 1991. SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV-transformed fibroblasts. Eur. J. Cancer. 27:58-62.
23. Mettouchi, A., F. Cabon, N. Montreau, P. Vernier, G. Mercier, D. Blangy, H. Tricoire, P. Vigier, and B. Binetruy. 1994. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J. 13:5668-5678.
24. Vial, E., and M. Castellazzi. 2000. Down-regulation of the extracellular matrix protein SPARC in vSrc-v and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo. Oncogene. 19:1772-1782.
25. Ledda, F., A.I. Bravo, S. Adris, L. Bover, J. Mordoh, and O.L. Podhajcer. 1997. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3:171-176.
26. Gilmour, D.T., G.J. Lyon, M.B. Carlton, J.R. Sanes, M.J. Cunningham, J.R. Anderson, B.L. Hogan, M.J. Evans, and W.H. Colledge. 1998. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J. 17:1860-1870.
27. Norose, K., J.I. Clark, N.A. Syed, A. Basu, E. Heber-Katz, E.H. Sage, and C.C. Howe. 1998. SPARC deficiency leads to early-onset cataractogenesis. Invest. Ophthalmol. Vis. Sci. 39:2674-2680.
28. Bassuk, J.A., T. Birkebak, J.D. Rothmier, J.M. Clark, A. Bradshaw, P.J. Muchowski, C.C. Howe, J.I. Clark, and E.H. Sage. 1999. Disruption of the Sparc locus in mice alters the differentiation of lenticular epithelial cells and leads to cataract formation. Exp. Eye Res. 68:321-331.
29. Delany, A.M., M. Amling, M. Priemel, C. Howe, R. Baron, and E. Canalis. 2000. Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin. Invest. 105:915-923.
30. Yan, Q., J.I. Clark, T.N. Wight, and E.H. Sage. 2002. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J. Cell Sci. 1:11-18.
31. Di Carlo, E., M.G. Diodoro, K. Boggio, A. Modesti, M. Modesti, P. Nanni, G. Forni, and P. Musiani. 1999. Analysis of mammary carcinoma onset and progression in HER2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 79:1261-1269.
32. Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi L., C. Melani, M. Giovarelli, I. Rossi, C. De Giovanni, P. Nanni, P. Brouchard, S. Wolf, A. Modesti, P. Musiani, P.L. Lollini, M.P. Colombo, and G. Forni. 1998. IL12-mediated prevention of spontaneous mammary adenocarcinoma in HER2/neu transgenic mice. J. Exp. Med. 188:589-596.
33. Stoppacciaro, A., C. Melani, M. Parenza, A. Mastracchio, C. Bassi, C. Baroni, G. Parmiani, and M.P. Colombo. 1993. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 78:151-161.
34. Wiseman, B.S., and Z. Werb. 2002. Stromal effects on mammary gland development and breast cancer. Science. 296:1046-1049.
35. Mok, S.C., W.Y. Chan, K.K. Wong, M.G. Muto, and R.S. Berkowitz. 1996. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 12:1895-1901.
36. Mok, S.C., K.K. Wong, R.K. Chan, C.C. Lau, S.W. Tsao, R.C. Knapp, and R.S. Berkowitz. 1994. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol. Oncol. 52:247-252.
37. Yiu, G.K., W.Y. Chan, S.W. Ng, P.S. Chan, K.K. Cheung, R.S. Berkowitz, and S.C. Mok. 2000. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159:609-612.
38. Dhanesuan, N., J.A. Sharp, T. Blick, J.T. Price, and E.W. Thompson. 2002. Doxycycline-inducible expression of SPARC/osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res. Treat. 75:73-85.
39. Rempel, S.A., S. Ge, and J.A. Gutierrez. 1999. SPARC: a potential diagnostic marker of invasive meningiomas. Clin. Cancer Res. 5:237-241.
40. Golembieski, W.A., S. Ge, K. Nelson, T. Mikkelsen, and S.A. Rempel. 1999. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int. J. Dev. Neurosci. 17:463-472.
41. Schultz, C., N. Lemke, S. Ge, W.A. Golembieski, and S.A. Rempel, 2002. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res. 62:6270-6277.
42. Xia, M., D. Leppert, S.L. Hauser, S.P. Sreedharan, P.J. Nelson, A. Krensky, and E.J. Goetzl. 1996. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J. Immunol. 156:160-167.
43. Leppert, D., E. Waubant, R. Galardy, N. Bunnett, and S.L. Hauser. 1995. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:4379-4389.
44. Ratzinger, R.G., P. Stoizner, S. Ebner, M.B. Lutz, G.T. Layton, C. Rainer, R.M. Senior, J.M. Shipley, P. Fritsch, G. Schuler, and N. Romani. 2002. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J. Immunol. 168:4361-4371.
45. Francki, A., A.D. Bradshaw, J.A. Bassuk, C.C. Howe, W.G. Couser, and E.H. Sage. 1999. SPARC regulates the expression of collagen Type I and transforming growth factor-β1 in mesangial cells. J. Biol. Chem. 274:32145-32152.
46. Hazelbag S.A. Gorter, G.G. Kenter, L. van der Broke, and G. Fleuren. 2000. Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Pathol. Internat. 50:884-890.
47. Folkman, J. 1985. Tumor angiogenesis. Adv. Canc. Res. 43:175-203.
48. Ganss, R., and D. Hanahan. 1998. Tumor microenvironment can restrict the effectivness of activated antitumor lymphocytes. Cancer Res. 58:4673-4681.
49. Spiotto, M.T., P. Yu, D.A. Rowley, M.J. Nishimura, S.C. Meredith, T.F. Gayewski, Y. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737-747.
50. Di Carlo, E., G. Forni, P.L. Lollini, M.P. Colombo, A. Modesti, and P. Musiani. 2001. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 97:339-345.
51. Holash, J., S.J. Wiegand, and G.D. Yancopoulus. 1999. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 18:5356-5362.
52. Sage, E.H. 1997. Terms of attachment: SPARC and tumorigenesis. Nat. Med. 3:144-146.
53. Iruela-Arispe, M.L., P. Hasselaar, and E.H. Sage. 1991. Differential expression of extracellular matrix proteins is correlated with angiogenesis in vitro. Lab. Invest. 64:174-186.
54. Vajkoczy, P., M.D. Menger, R. Goldbrunner, S. Ge, T.A. Fong, B. Vollmar, L. Schilling, A. Ullrich, K.P. Hirth, J.C. Tonn, et al. 2000. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int. J. Cancer. 87:261-268.
55. Poulakkaien P., A.D. Brashow, T.R. Kyriakides, M. Reed, R. Brekken, T. Wight, P. Bornstein, B. Ratkner, and E.H. Sage. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am. J. Pathol. 167:627-635.
56. Brekken R.A., P. Poulakkainen, D.C. Graves, G. Workman, S.R. Lubkin and E.H. Sage. 2003. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.J. Clin. Invest. 111:487-495.
57. Palmieri, D., L. Carmadella, V. Ulivi, G. Guasco, and P. Manduca. 2000. Trimer carboxyl propeptide of collagen I produced by mature osteoblasts is chemotactic for endothelial cells. J. Biol. Chem. 275:32658-32663.
58. Hamano Y., M. Zeisberg, H. Sugimotu, J. C. lively, Y. Maeshima, C. Yang, R. O. Hynes, Z. Werb, A. Sudhakar, and R. Kalluri. Physiological levels of tumstatin, a fragment of collagen type IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αvβ3 integrin. Cancer Cell. 3:589-601.
59. Gresser, I., and C. Bourali-Maury. 1972. Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastases in mice. Nature. 236:78-79.
60. Isakov, N., M. Feldman, and S. Segal. 1982. An immune response against the alloantigens of the 3LL Lewis lung carcinoma prevents the growth of lung metastases, but not of local allografts. Invasion Metastasis. 2:12-32.